{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B+Acute+Lymphoblastic+Leukemia&page=4", "query": { "condition": "Refractory B Acute Lymphoblastic Leukemia", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 606, "total_pages": 61, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B+Acute+Lymphoblastic+Leukemia&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B+Acute+Lymphoblastic+Leukemia&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T06:28:31.215Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00185679", "title": "Haploid Allogeneic Transplant Using the CliniMACS System", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors", "Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase", "Myelodysplastic Syndrome (MDS) - High and Intermediate Risk", "Non-Hodgkin's Lymphoma (NHL)", "Chronic Lymphocytic Leukemia (CLL) - Refractory" ], "interventions": [ { "name": "CliniMACS System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Ginna Laport", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 13, "start_date": "2001-11", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2015-03-09", "last_synced_at": "2026-11-15T06:28:31.215Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00185679" }, { "nct_id": "NCT00324324", "title": "Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Infection", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Ovarian Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "moxifloxacin hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 240, "start_date": "2006-05", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-11-15T06:28:31.215Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324324" }, { "nct_id": "NCT00024180", "title": "FR901228 in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-01", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2013-01-31", "last_synced_at": "2026-11-15T06:28:31.215Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024180" }, { "nct_id": "NCT07257419", "title": "CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Pediatric ALL", "Hematopoietic Cell Transplantation", "Hematologic Malignancy" ], "interventions": [ { "name": "Anti-Thymocyte Globulin (Rabbit)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "CliniMACS System", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 70, "start_date": "2026-10-03", "completion_date": "2035-12", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-11-15T06:28:31.215Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07257419" }, { "nct_id": "NCT00042900", "title": "Pyroxamide in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous Condition", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "pyroxamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-04", "completion_date": "2002-09", "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-11-15T06:28:31.215Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00042900" }, { "nct_id": "NCT03448393", "title": "CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Leukemia, Lymphocytic, B Cell", "B-Cell Lymphoma", "B-Cell Leukemia", "Acute Lymphoid Leukemia", "B-Non Hodgkin Lymphoma", "B-NHL", "B-All", "Acute Lymphoblastic Leukemia", "Acute Lymphocytic Leukemia" ], "interventions": [ { "name": "CD19/CD22 CAR T-Cells", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Apheresis", "type": "PROCEDURE" }, { "name": "Anti-emetic", "type": "OTHER" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI Brain", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone marrow biopsy", "type": "PROCEDURE" }, { "name": "Cardiac MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "3 Years to 39 Years" }, "enrollment_count": 54, "start_date": "2018-03-26", "completion_date": "2025-01-13", "has_results": true, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-11-15T06:28:31.215Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03448393" }, { "nct_id": "NCT01129193", "title": "AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Prolymphocytic Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "Testicular Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Pharmacodynamic Studies", "type": "OTHER" }, { "name": "Fatigue Inventory", "type": "OTHER" }, { "name": "Pharmacogenomic studies", "type": "OTHER" }, { "name": "AR-42", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Amir Mortazavi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2010-05-04", "completion_date": "2017-01-07", "has_results": false, "last_update_posted_date": "2018-06-04", "last_synced_at": "2026-11-15T06:28:31.215Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01129193" }, { "nct_id": "NCT06173518", "title": "A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia", "Relapsed or Refractory B Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "AUTO1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Autolus Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "0 Years to 18 Years" }, "enrollment_count": 30, "start_date": "2023-11-16", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-11-13", "last_synced_at": "2026-11-15T06:28:31.215Z", "location_count": 10, "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06173518" }, { "nct_id": "NCT02109224", "title": "Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult B Acute Lymphoblastic Leukemia", "Chronic Lymphocytic Leukemia", "Cutaneous B-Cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "HIV Infection", "Intraocular Lymphoma", "Multicentric Angiofollicular Lymphoid Hyperplasia", "Nodal Marginal Zone Lymphoma", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Plasma Cell Myeloma", "Small Intestinal Lymphoma", "Splenic Marginal Zone Lymphoma", "Testicular Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2014-09", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2015-08-20", "last_synced_at": "2026-11-15T06:28:31.215Z", "location_count": 7, "location_summary": "Los Angeles, California • Baltimore, Maryland • St Louis, Missouri + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02109224" }, { "nct_id": "NCT00003885", "title": "Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Our Lady of Mercy Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "1997-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-06", "last_synced_at": "2026-11-15T06:28:31.215Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003885" } ] }